Oncotarget

Researchers Question Editorial Bias in COVID-19 Vaccine Debate

Feb 16, 2026
A commentary chronicles a two-year struggle to publish a case report linking an mRNA COVID-19 vaccine to a rare blood cancer. It details repeated rejections, alleged withdrawals after positive review, and examples of reviewer comments that the authors say misrepresented their work. The piece questions whether editorial choices shaped the perceived scientific consensus and calls for more transparent publishing practices.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Repeated Rejections Delayed Publication

  • Authors documented a two-year effort rejecting a case report linking mRNA COVID-19 vaccines to rare blood cancers before publication in Oncotarget.
  • The manuscript faced 16 rejections, most without external peer review, and one journal withdrew acceptance twice after review.
ANECDOTE

Case Report And Review That Faced 16 Rejections

  • The contested paper combined a case report of acute lymphoblastic leukemia after an mRNA vaccine with a literature review of hematological malignancies.
  • Three journals ran peer review, one accepted twice then withdrew, illustrating the authors' publication ordeal.
INSIGHT

Editorial Pushback Framed As Scientific Judgment

  • Authors claim editorial decisions, not scientific merit, blocked publication and misrepresented their content in reviewer feedback.
  • Examples include a rejection asserting mRNA vaccines cannot cause cancer because they don't integrate into DNA, which authors called overly narrow.
Get the Snipd Podcast app to discover more snips from this episode
Get the app